Art

J-GLOBAL ID：201902280056531802   Reference number：19A0239939

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial

難治性大細胞型B細胞リンパ腫(ZUMA-1)におけるアキシカブテンシルレオセルの長期安全性および活性:単腕多施設第1相試験【JST・京大機械翻訳】

Author (31)： Locke Frederick L (Moffitt Cancer Center, Tampa, FL, USA) ,  Ghobadi Armin (Washington University School of Medicine, St Louis, MO, USA) ,  Jacobson Caron A (Dana-Farber Cancer Institute, Boston, MA, USA) ,  Miklos David B (Stanford University School of Medicine, Stanford, CA, USA) ,  Lekakis Lazaros J (University of Miami Health System, Sylvester Comprehensive Cancer Center, Miami, FL, USA) ,  Oluwole Olalekan O (Vanderbilt-Ingram Cancer Center, Nashville, TN, USA) ,  Lin Yi (Mayo Clinic, Rochester, MN, USA) ,  Braunschweig Ira (Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA) ,  Hill Brian T (Cleveland Clinic Foundation, Cleveland, OH, USA) ,  Timmerman John M (UCLA David Geffen School of Medicine, Los Angeles, CA, USA) ,  Deol Abhinav (Karmanos Cancer Center, Wayne State University, Detroit, MI, USA) ,  Reagan Patrick M (University of Rochester Medical Center, Rochester, NY, USA) ,  Stiff Patrick (Loyola University Chicago Stritch School of Medicine, Maywood, IL, USA) ,  Flinn Ian W (Sarah Cannon Research Institute, Nashville, TN, USA) ,  Farooq Umar (University of Iowa, Iowa City, IA, USA) ,  Goy Andre (John Theurer Cancer Center, Hackensack, NJ, USA) ,  McSweeney Peter A (Colorado Blood Cancer Institute, Denver, CO, USA) ,  Munoz Javier (Banner MD Anderson Cancer Center, Gilbert, AZ, USA) ,  Siddiqi Tanya (City of Hope National Medical Center, Duarte, CA, USA) ,  Chavez Julio C (Moffitt Cancer Center, Tampa, FL, USA) ,  Herrera Alex F (City of Hope National Medical Center, Duarte, CA, USA) ,  Bartlett Nancy L (Washington University School of Medicine, St Louis, MO, USA) ,  Wiezorek Jeffrey S (Kite, Santa Monica, CA, USA) ,  Navale Lynn (Kite, Santa Monica, CA, USA) ,  Xue Allen (Kite, Santa Monica, CA, USA) ,  Jiang Yizhou (Kite, Santa Monica, CA, USA) ,  Bot Adrian (Kite, Santa Monica, CA, USA) ,  Rossi John M (Kite, Santa Monica, CA, USA) ,  Kim Jenny J (Kite, Santa Monica, CA, USA) ,  Go William Y (Kite, Santa Monica, CA, USA) ,  Neelapu Sattva S (University of Texas MD Anderson Cancer Center, Houston, TX, USA)
Material： Lancet Oncology  (Lancet Oncol)
Volume： 20  Issue： 1  Page： 31-42  Publication year： 2019 
JST Material Number： W1266A  ISSN： 1470-2045  Document type： Article
Article type： 原著論文  Country of issue： Netherlands (NLD)  Language： ENGLISH (EN)

Abstract/Point： Axicabtagene ciloleucel is an ...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=19A0239939&from=J-GLOBAL&jstjournalNo=W1266A") }}

Thesaurus term： T cell ,  *safety ,  dose ,  therapy ,  recurrence ,  *phase 1 study ,  death ,  *B cell lymphoma ,  drug therapy ,  *monophase
Semi thesaurus term： 有害事象 ,  生存期間 ,  全生存期間 ,  エンドポイント ,  完全寛解 , 【Automatic Indexing@JST】

JST classification (2)： Blood cell tumors(=neoplasms)  (GK04000M) ,  Drug therapy(=pharmacotherapy)for tumors  (GE03032C)

Terms in the title (7)： 大細胞型B細胞リンパ腫 ,  長期 ,  安全性 ,  活性 ,  腕 ,  施設 ,  第1相試験